1	Effects	Effect	B-NP	NNS	O	0	ROOT	16	Effects
2	of	of	B-PP	IN	O	1	NMOD	0
3	spironolactone	spironolactone	B-NP	NN	O	2	PMOD	0
4	on	on	B-PP	IN	O	1	NMOD	0
5	corneal	corneal	B-NP	JJ	O	7	NMOD	0
6	allograft	allograft	I-NP	NN	O	7	NMOD	0
7	survival	survival	I-NP	NN	O	4	PMOD	5	survival
8	in	in	B-PP	IN	O	7	NMOD	0
9	the	the	B-NP	DT	O	10	NMOD	0
10	rat	rat	I-NP	NN	O	8	PMOD	0
11	.	.	O	.	O	1	P	0

1	PURPOSE	PURPOSE	B-NP	NN	O	3	NMOD	0
2	:	:	O	:	O	1	P	0
3	Spironolactone	Spironolactone	B-NP	NN	O	4	SUB	0
4	has	have	B-VP	VBZ	O	0	ROOT	0
5	recently	recently	I-VP	RB	O	4	VMOD	0
6	been	be	I-VP	VBN	O	4	VC	0
7	shown	show	I-VP	VBN	O	6	VC	0
8	to	to	I-VP	TO	O	9	VMOD	0
9	have	have	I-VP	VB	O	7	VMOD	0
10	suppressive	suppressive	B-NP	JJ	O	11	NMOD	0
11	effects	effect	I-NP	NNS	O	9	OBJ	0
12	on	on	B-PP	IN	O	9	VMOD	0
13	several	several	B-NP	JJ	O	12	PMOD	0
14	immunoactive	immunoactive	I-NP	JJ	O	13	NMOD	0
15	and	and	I-NP	CC	O	13	NMOD	0
16	proinflammatory	proinflammatory	I-NP	JJ	B-protein	13	NMOD	0
17	cytokines	cytokine	I-NP	NNS	I-protein	13	NMOD	0
18	.	.	O	.	O	4	P	0

1	In	In	B-PP	IN	O	6	VMOD	0
2	this	this	B-NP	DT	O	3	NMOD	0
3	study	study	I-NP	NN	O	1	PMOD	0
4	,	,	O	,	O	6	P	0
5	we	we	B-NP	PRP	O	6	SUB	0
6	investigated	investigate	B-VP	VBD	O	0	ROOT	0
7	the	the	B-NP	DT	O	8	NMOD	0
8	effects	effect	I-NP	NNS	O	6	OBJ	16	effects
9	of	of	B-PP	IN	O	8	NMOD	0
10	spironolactone	spironolactone	B-NP	NN	O	9	PMOD	0
11	on	on	B-PP	IN	O	8	NMOD	0
12	the	the	B-NP	DT	O	13	NMOD	0
13	prevention	prevention	I-NP	NN	O	11	PMOD	18	prevention
14	of	of	B-PP	IN	O	13	NMOD	0
15	corneal	corneal	B-NP	JJ	O	17	NMOD	0
16	allograft	allograft	I-NP	NN	O	17	NMOD	0
17	rejection	rejection	I-NP	NN	O	14	PMOD	5	rejection
18	in	in	B-PP	IN	O	17	NMOD	0
19	a	a	B-NP	DT	O	27	NMOD	0
20	MHC	MHC	I-NP	NN	B-cell_line	27	NMOD	0
21	class	class	I-NP	NN	I-cell_line	27	NMOD	0
22	I/II	I/II	I-NP	NN	I-cell_line	27	NMOD	0
23	mismatch	mismatch	I-NP	NN	I-cell_line	27	NMOD	0
24	rat	rat	I-NP	NN	I-cell_line	27	NMOD	0
25	corneal	corneal	I-NP	NN	I-cell_line	27	NMOD	0
26	transplant	transplant	I-NP	NN	I-cell_line	27	NMOD	19	transplant
27	model	model	I-NP	NN	I-cell_line	18	PMOD	0
28	.	.	O	.	O	6	P	0

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	0
3	Grafted	Graft	B-NP	VBN	O	4	NMOD	0
4	animals	animal	I-NP	NNS	O	9	SUB	0
5	for	for	B-PP	IN	O	4	NMOD	0
6	corneal	corneal	B-NP	JJ	O	8	NMOD	0
7	survival	survival	I-NP	NN	O	8	NMOD	5	survival
8	analysis	analysis	I-NP	NN	O	5	PMOD	0
9	were	be	B-VP	VBD	O	1	NMOD	0
10	assigned	assign	I-VP	VBN	O	9	VC	0
11	to	to	I-VP	TO	O	12	VMOD	0
12	receive	receive	I-VP	VB	O	10	VMOD	0
13	either	either	O	CC	O	15	NMOD	0
14	spironolactone	spironolactone	B-NP	NN	O	15	NMOD	0
15	suspension	suspension	I-NP	NN	O	12	OBJ	0
16	(	(	O	(	O	12	VMOD	0
17	orally	orally	B-ADVP	RB	O	12	VMOD	0
18	,	,	O	,	O	12	P	0
19	100	100	B-NP	CD	O	20	NMOD	0
20	mg/kg/day	mg/kg/day	I-NP	NN	O	24	NMOD	0
21	,	,	O	,	O	24	P	0
22	n	n	B-NP	NN	O	24	SUB	0
23	=	=	B-VP	SYM	O	24	VMOD	0
24	7	7	B-NP	CD	O	12	VMOD	0
25	)	)	O	)	O	24	NMOD	0
26	,	,	O	,	O	12	P	0
27	phosphate-buffered	phosphate-buffered	B-NP	JJ	O	28	NMOD	0
28	saline	saline	I-NP	NN	O	12	OBJ	0
29	(	(	O	(	O	28	NMOD	0
30	PBS	PBS	B-NP	NNS	O	29	ROOT	0
31	,	,	O	,	O	30	P	0
32	orally	orally	B-ADVP	RB	O	30	NMOD	0
33	,	,	O	,	O	32	P	0
34	same	same	B-NP	JJ	O	35	NMOD	0
35	volume	volume	I-NP	NN	O	39	NMOD	0
36	as	as	B-PP	IN	O	35	NMOD	0
37	spironolactone	spironolactone	B-NP	NN	O	36	PMOD	0
38	,	,	O	,	O	39	P	0
39	n	n	B-NP	NN	O	33	NMOD	0
40	=	=	B-VP	SYM	O	39	NMOD	0
41	9	9	B-NP	CD	O	40	AMOD	0
42	)	)	O	)	O	39	NMOD	0
43	or	or	O	CC	O	39	NMOD	0
44	remained	remain	B-VP	VBD	O	43	DEP	0
45	untreated	untreated	B-ADJP	JJ	O	44	PRD	0
46	(	(	O	(	O	50	DEP	0
47	n	n	B-NP	NN	O	50	DEP	0
48	=	=	B-VP	SYM	O	47	NMOD	0
49	16	16	B-NP	CD	O	48	AMOD	0
50	)	)	O	)	O	45	AMOD	0
51	.	.	O	.	O	39	P	0

1	Additional	Additional	B-NP	JJ	O	3	NMOD	0
2	grafted	grafted	I-NP	JJ	O	3	NMOD	19	grafted
3	rats	rat	I-NP	NNS	O	19	SUB	0
4	treated	treat	B-VP	VBN	O	3	NMOD	19	treated
5	with	with	B-PP	IN	O	4	VMOD	0
6	spironolactone	spironolactone	B-NP	NN	O	13	NMOD	0
7	(	(	O	(	O	11	DEP	0
8	n	n	B-NP	NN	O	10	SUB	0
9	=	=	B-VP	SYM	O	10	VMOD	0
10	6	6	B-NP	CD	O	11	DEP	0
11	)	)	O	)	O	6	NMOD	0
12	or	or	O	CC	O	13	NMOD	0
13	PBS	PBS	B-NP	NNS	B-protein	5	PMOD	0
14	(	(	O	(	O	18	DEP	0
15	n	n	B-NP	NN	O	17	SUB	0
16	=	=	B-VP	SYM	O	17	VMOD	0
17	8	8	B-NP	CD	O	18	DEP	0
18	)	)	O	)	O	13	NMOD	0
19	were	be	B-VP	VBD	O	0	ROOT	0
20	sacrificed	sacrifice	I-VP	VBN	O	19	VC	19	sacrificed
21	on	on	B-PP	IN	O	20	VMOD	0
22	day	day	B-NP	NN	O	21	PMOD	0
23	12	12	I-NP	CD	O	22	NMOD	0
24	for	for	B-PP	IN	O	20	VMOD	0
25	quantitative	quantitative	B-NP	JJ	O	27	NMOD	0
26	RT-PCR	RT-PCR	I-NP	NN	O	27	NMOD	0
27	analysis	analysis	I-NP	NN	O	24	PMOD	0
28	for	for	B-PP	IN	O	27	NMOD	0
29	mechanistic	mechanistic	B-NP	JJ	O	30	NMOD	0
30	studies	study	I-NP	NNS	O	28	PMOD	0
31	.	.	O	.	O	19	P	0

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	0
3	Mean	Mean	B-NP	NN	O	8	NMOD	0
4	(	(	O	(	O	6	DEP	0
5	+/-SEM	+/-SEM	B-NP	NN	O	6	DEP	0
6	)	)	O	)	O	3	NMOD	0
7	graft	graft	B-NP	NN	O	8	NMOD	0
8	survival	survival	I-NP	NN	O	9	SUB	5	survival
9	was	be	B-VP	VBD	O	1	NMOD	0
10	significantly	significantly	I-VP	RB	O	9	VMOD	0
11	prolonged	prolong	I-VP	VBN	O	9	VC	17	prolonged
12	in	in	B-PP	IN	O	11	VMOD	0
13	animals	animal	B-NP	NNS	O	12	PMOD	0
14	receiving	receive	B-VP	VBG	O	13	NMOD	19	receiving
15	spironolactone	spironolactone	B-NP	NN	O	14	OBJ	0
16	(	(	O	(	O	21	DEP	0
17	14.9	14.9	B-NP	CD	O	19	AMOD	0
18	+/-	+/-	I-NP	CC	O	19	AMOD	0
19	2.0	2.0	I-NP	CD	O	20	NMOD	0
20	days	day	I-NP	NNS	O	21	DEP	0
21	)	)	O	)	O	15	NMOD	0
22	compared	compare	B-PP	VBN	O	11	VMOD	0
23	with	with	B-PP	IN	O	22	PMOD	0
24	both	both	O	CC	O	38	NMOD	0
25	PBS-treated	PBS-treated	O	JJ	O	38	NMOD	19	treated
26	(	(	O	(	O	35	DEP	0
27	12.3	12.3	B-NP	CD	O	29	AMOD	0
28	+/-	+/-	I-NP	CC	O	29	AMOD	0
29	1.2	1.2	I-NP	CD	O	30	NMOD	0
30	days	day	I-NP	NNS	O	34	NMOD	0
31	,	,	O	,	O	34	P	0
32	p	p	B-NP	NN	O	34	SUB	0
33	=	=	B-VP	SYM	O	34	VMOD	0
34	0.007	0.007	B-NP	CD	O	35	DEP	0
35	)	)	O	)	O	25	AMOD	0
36	and	and	O	CC	O	38	NMOD	0
37	untreated	untreated	B-NP	JJ	O	38	NMOD	19	untreated
38	controls	control	I-NP	NNS	O	23	PMOD	0
39	(	(	O	(	O	48	DEP	0
40	13.0	13.0	B-NP	CD	O	42	AMOD	0
41	+/-	+/-	I-NP	CC	O	42	AMOD	0
42	1.0	1.0	I-NP	CD	O	43	NMOD	0
43	days	day	I-NP	NNS	O	48	DEP	0
44	,	,	O	,	O	48	P	0
45	p	p	B-NP	NN	O	48	DEP	0
46	=	=	B-VP	SYM	O	45	NMOD	0
47	0.01	0.01	B-NP	CD	O	46	AMOD	0
48	)	)	O	)	O	38	NMOD	0
49	.	.	O	.	O	1	P	0

1	We	We	B-NP	PRP	O	2	SUB	0
2	found	find	B-VP	VBD	O	0	ROOT	0
3	a	a	B-NP	DT	O	4	NMOD	0
4	decrease	decrease	I-NP	NN	O	2	OBJ	18	decrease
5	in	in	B-PP	IN	O	4	NMOD	0
6	corneal	corneal	B-NP	JJ	O	7	NMOD	0
7	neovascularization	neovascularization	I-NP	NN	O	5	PMOD	3	neovascularization
8	in	in	B-PP	IN	O	4	NMOD	0
9	spironolactone-treated	spironolactone-treated	B-NP	JJ	O	10	NMOD	19	treated
10	rats	rat	I-NP	NNS	O	8	PMOD	0
11	compared	compare	B-PP	VBN	O	4	NMOD	0
12	with	with	B-PP	IN	O	11	VMOD	0
13	the	the	B-NP	DT	O	15	NMOD	0
14	PBS-treated	PBS-treated	I-NP	JJ	O	15	NMOD	19	treated
15	group	group	I-NP	NN	O	12	PMOD	0
16	,	,	O	,	O	2	P	0
17	although	although	B-SBAR	IN	O	2	VMOD	0
18	the	the	B-NP	DT	O	19	NMOD	0
19	difference	difference	I-NP	NN	O	20	SUB	0
20	was	be	B-VP	VBD	O	17	SBAR	0
21	not	not	O	RB	O	20	VMOD	0
22	statistically	statistically	B-ADJP	RB	O	20	VMOD	0
23	significant	significant	I-ADJP	JJ	O	20	PRD	0
24	.	.	O	.	O	2	P	0

1	Spironolactone	Spironolactone	B-NP	NN	O	2	SUB	0
2	affected	affect	B-VP	VBD	O	0	ROOT	16	affected
3	both	both	O	CC	O	16	NMOD	0
4	systemic	systemic	O	JJ	O	16	NMOD	0
5	(	(	O	(	O	12	DEP	0
6	down-regulation	down-regulation	B-NP	NN	O	12	DEP	18	down-regulation
7	of	of	B-PP	IN	O	6	NMOD	0
8	CD25+	CD25+	B-NP	JJ	B-cell_type	9	NMOD	0
9	cells	cell	I-NP	NNS	I-cell_type	7	PMOD	0
10	in	in	B-PP	IN	O	6	NMOD	0
11	spleen	spleen	B-NP	NN	O	10	PMOD	0
12	)	)	O	)	O	4	NMOD	0
13	and	and	O	CC	O	16	NMOD	0
14	local	local	B-NP	JJ	O	16	NMOD	0
15	immune	immune	I-NP	JJ	O	16	NMOD	0
16	response	response	I-NP	NN	O	2	OBJ	0
17	(	(	O	(	O	23	DEP	0
18	up-regulation	up-regulation	B-NP	NN	O	23	DEP	17	up-regulation
19	of	of	B-PP	IN	O	18	NMOD	0
20	IL-10	IL-10	B-NP	NN	B-protein	19	PMOD	0
21	in	in	B-PP	IN	O	18	NMOD	0
22	cornea	cornea	B-NP	NN	O	21	PMOD	0
23	)	)	O	)	O	16	NMOD	0
24	.	.	O	.	O	2	P	0

1	CONCLUSION	CONCLUSION	B-NP	NN	O	4	VMOD	0
2	:	:	O	:	O	4	P	0
3	We	We	B-NP	PRP	O	4	SUB	0
4	present	present	B-VP	VBP	O	0	ROOT	0
5	initial	initial	B-NP	JJ	O	6	NMOD	0
6	results	result	I-NP	NNS	O	4	OBJ	0
7	demonstrating	demonstrate	B-VP	VBG	O	6	NMOD	0
8	anti-inflammatory	anti-inflammatory	B-NP	JJ	O	9	NMOD	0
9	effects	effect	I-NP	NNS	O	7	OBJ	0
10	of	of	B-PP	IN	O	9	NMOD	0
11	spironolactone	spironolactone	B-NP	NN	O	10	PMOD	0
12	.	.	O	.	O	4	P	0

